Patent · US Active

Liquid formulation of a VEGF antagonist

US10576128B2 · kind B2 · utility

36Cited by

7References

14Claims

0Family size

Assignee

FORMYCON AG · DE

Inventor

Rainer Sigl · Puchheim, DE

Key dates

Filing date	Jan 26, 2017
Grant date	Mar 3, 2020
Priority date	—
Expiry date	Jan 26, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/71
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.